BioSpace News Archive

Catalent, Inc. announced the promotion of Thomas Castellano to serve as the company’s Senior Vice President and Chief Financial Officer effective June 1, 2021, succeeding Wetteny Joseph who will be leaving the company to become the Chief Financial Officer of Zoetis Inc.

Transposon technology efficiently generates active CAR-NK cells and has potential advantages compared to viral approaches Oral presentation highlighted at the American Society of Gene and Cell Therapy annual meeting

As new trade routes begin to emerge and competition intensifies in the Arctic, Spire is providing data to inform decisions on critical issues around climate change, navigation, and transportation within the region through its comprehensive data and weather forecasting services.

− Initiates Clinical Study of Biannual Dosing Regimen of Investigational Vutrisiran in hATTR Patients with Polyneuropathy, with Data Expected in 2022 Potentially Supporting sNDA Submission – − Introduces New ATTR Program Aimed at Achieving Annual Dosing Regimen with Highly Potent and Reversible Effects; Expected IND Filing at or Around Year-end 2022 –

Zoetis Inc. (NYSE:ZTS) today announced leadership changes that will accelerate its long-term growth strategy in key markets and add new talent to its executive team. Glenn David, Executive Vice President and Chief Financial Officer (CFO) for Zoetis, has been named Executive Vice President and Group President, overseeing International Operations and other business units, effective June 1, 2021.

IMV continues to add industry expertise with appointment of Dr. Michael Kalos, an internationally recognized expert in T cell therapy and immunotherapy James Hall to retire at the AGM after 11 years as a board member

BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, expected in fourth quarter of 2021 Pre-commercial and manufacturing activities underway to support potential launch of omidubicel in 2022 Phase 1/2 clinical trial of allogeneic, off-the-shelf GDA-201 in NHL planned with IND submission anticipated in the second half of 2021

AngioSoma, Inc. (OTC PINK:SOAN) has added Darryl Morris as a Strategic Economic Advisor. Morris has over three decades of economic, strategic, and market intelligence experience working with companies, such as Abbott Laboratories.

BioArctic AB announced that the Japanese Patent Office has allowed the company’s Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimer’s disease.

IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced that the CE Mark certificates for its IRRAflow system and the company’s ISO13485:2016 certification have been transferred to a new notified body, DEKRA.